|
US7982036B2
(en)
|
2007-10-19 |
2011-07-19 |
Avila Therapeutics, Inc. |
4,6-disubstitued pyrimidines useful as kinase inhibitors
|
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
|
EP2300013B2
(en)
|
2008-05-21 |
2024-11-13 |
Takeda Pharmaceutical Company Limited |
Phosphorous derivatives as kinase inhibitors
|
|
NZ603525A
(en)
|
2008-06-27 |
2015-02-27 |
Celgene Avilomics Res Inc |
Pyrimidine based compound and uses thereof
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
JP5918693B2
(ja)
|
2009-05-05 |
2016-05-18 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
Ｅｇｆｒ阻害剤及び疾患の治療方法
|
|
US8367689B2
(en)
*
|
2009-05-06 |
2013-02-05 |
Portola Pharmaceuticals, Inc. |
Inhibitors of JAK
|
|
JP2012529535A
(ja)
|
2009-06-12 |
2012-11-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼモジュレーターとして有用なニコチンアミド化合物
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
US8466155B2
(en)
*
|
2009-10-02 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Pyrimidines
|
|
AU2010339456A1
(en)
|
2009-12-30 |
2012-07-05 |
Celgene Avilomics Research, Inc. |
Ligand-directed covalent modification of protein
|
|
WO2011146313A1
(en)
|
2010-05-19 |
2011-11-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
|
BR112012029647A2
(pt)
|
2010-05-21 |
2016-08-02 |
Chemilia Ab |
novos derivados de pirimidinas
|
|
US8354420B2
(en)
|
2010-06-04 |
2013-01-15 |
Genentech, Inc. |
Aminopyrimidine derivatives as LRRK2 inhibitors
|
|
CN105566229A
(zh)
|
2010-08-10 |
2016-05-11 |
西建阿维拉米斯研究公司 |
Btk抑制剂的苯磺酸盐及其用途和制备方法
|
|
SG10201508958WA
(en)
|
2010-11-01 |
2015-11-27 |
Celgene Avilomics Res Inc |
Heterocyclic Compounds And Uses Thereof
|
|
US9238629B2
(en)
|
2010-11-01 |
2016-01-19 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
EP2637502B1
(en)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutant-selective egfr inhibitors and uses thereof
|
|
SI2638031T1
(en)
|
2010-11-10 |
2018-02-28 |
Genentech, Inc. |
Pyrazole aminopyrimidine derivatives as LRRK2 modulators
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
JP5886411B2
(ja)
|
2011-03-24 |
2016-03-16 |
ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ |
新規のピリミジン誘導体
|
|
EP3628665B1
(en)
|
2011-04-01 |
2022-11-02 |
University of Utah Research Foundation |
Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
|
|
US8703767B2
(en)
|
2011-04-01 |
2014-04-22 |
University Of Utah Research Foundation |
Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
|
|
HRP20240097T1
(hr)
|
2011-04-22 |
2024-03-29 |
Signal Pharmaceuticals, Llc |
Supstituirani diaminokarboksamid i diaminokarbonitril pirimidini, njihovi pripravci i postupci liječenja s njima
|
|
CA2834049C
(en)
|
2011-04-25 |
2018-05-22 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
EP2704572B1
(en)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
MY161925A
(en)
|
2011-07-27 |
2017-05-15 |
Astrazeneca Ab |
2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
|
|
US9273056B2
(en)
|
2011-10-03 |
2016-03-01 |
The University Of North Carolina At Chapel Hill |
Pyrrolopyrimidine compounds for the treatment of cancer
|
|
JP2014532658A
(ja)
*
|
2011-10-28 |
2014-12-08 |
セルジーン アヴィロミクス リサーチ， インコーポレイテッド |
ブルトン型チロシンキナーゼ疾患または障害を治療する方法
|
|
US9586965B2
(en)
|
2012-01-13 |
2017-03-07 |
Acea Biosciences Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
US9464089B2
(en)
*
|
2012-01-13 |
2016-10-11 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2013207712B2
(en)
|
2012-01-13 |
2017-08-31 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses as anticancer agents.
|
|
WO2013108754A1
(ja)
|
2012-01-17 |
2013-07-25 |
アステラス製薬株式会社 |
ピラジンカルボキサミド化合物
|
|
CA2866857C
(en)
|
2012-03-15 |
2021-03-09 |
Celgene Avilomics Research, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
|
JP6317319B2
(ja)
|
2012-03-15 |
2018-04-25 |
セルジーン シーエーアール エルエルシー |
上皮成長因子受容体キナーゼ阻害剤の固体形態
|
|
JP6469567B2
(ja)
*
|
2012-05-05 |
2019-02-13 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
|
|
WO2013173518A1
(en)
*
|
2012-05-16 |
2013-11-21 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
HK1206338A1
(en)
*
|
2012-05-22 |
2016-01-08 |
北卡罗来纳大学教堂山分校 |
Pyrimidine compounds for the treatment of cancer
|
|
LT3495367T
(lt)
|
2012-06-13 |
2021-02-25 |
Incyte Holdings Corporation |
Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
EP2892538A4
(en)
*
|
2012-09-04 |
2016-04-20 |
Celgene Avilomics Res Inc |
METHOD FOR TREATING BRUTON TYROSINE KINASE ILLNESS OR DISORDER
|
|
US9296703B2
(en)
|
2012-10-04 |
2016-03-29 |
University Of Utah Research Foundation |
Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
|
|
CA2887435A1
(en)
|
2012-10-04 |
2014-04-10 |
University Of Utah Research Foundation |
Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
|
|
EP2909211A4
(en)
|
2012-10-17 |
2016-06-22 |
Univ North Carolina |
PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
|
US8765762B2
(en)
|
2012-10-25 |
2014-07-01 |
Usher III, Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
|
|
US9227976B2
(en)
|
2012-10-25 |
2016-01-05 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
|
WO2014081714A2
(en)
*
|
2012-11-20 |
2014-05-30 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
WO2014081712A2
(en)
*
|
2012-11-20 |
2014-05-30 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
US20140142128A1
(en)
*
|
2012-11-20 |
2014-05-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with bruton's tyrosine kinase
|
|
EP2922826A4
(en)
*
|
2012-11-20 |
2016-08-03 |
Celgene Avilomics Res Inc |
METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE
|
|
WO2014085225A1
(en)
*
|
2012-11-27 |
2014-06-05 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EP2935226A4
(en)
|
2012-12-21 |
2016-11-02 |
Celgene Avilomics Res Inc |
HETEROARYL COMPOUNDS AND USES THEREOF
|
|
JP2016506930A
(ja)
|
2013-01-25 |
2016-03-07 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
炎症性腸疾患を処置するための化合物および方法
|
|
US9561228B2
(en)
|
2013-02-08 |
2017-02-07 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
|
US20140357636A1
(en)
*
|
2013-02-21 |
2014-12-04 |
Wayne Rothbaum |
Treatment of Skeletal-Related Disorders
|
|
AR094929A1
(es)
|
2013-02-28 |
2015-09-09 |
Bristol Myers Squibb Co |
Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
|
|
WO2014134391A1
(en)
|
2013-02-28 |
2014-09-04 |
Bristol-Myers Squibb Company |
Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
|
|
JP6433974B2
(ja)
|
2013-03-14 |
2018-12-05 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
|
|
WO2014140582A1
(en)
|
2013-03-14 |
2014-09-18 |
Respivert Limited |
Kinase inhibitors
|
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
|
LT2986610T
(lt)
|
2013-04-19 |
2018-04-10 |
Incyte Holdings Corporation |
Bicikliniai heterociklai, kaip fgfr inhibitoriai
|
|
SI2989106T1
(sl)
|
2013-04-25 |
2017-07-31 |
Beigene, Ltd. |
Zlite heterociklične spojine kot inhibitorji beljakovinske kinaze
|
|
WO2014182593A1
(en)
*
|
2013-05-06 |
2014-11-13 |
Clovis Oncology, Inc. |
Salts of an epidermal growth factor receptor kinase inhibitor
|
|
GB201309085D0
(en)
|
2013-05-20 |
2013-07-03 |
Redx Pharma Ltd |
Compounds
|
|
EP3483167A1
(en)
|
2013-06-26 |
2019-05-15 |
AbbVie Inc. |
Primary carboxamides as btk inhibitors
|
|
KR102173433B1
(ko)
*
|
2013-07-11 |
2020-11-04 |
에이시아 바이오사이언시스 인코포레이티드. |
키나아제 억제제로써의 피리미딘 유도체
|
|
CN105377835B
(zh)
*
|
2013-07-11 |
2018-08-17 |
贝达药业股份有限公司 |
酪氨酸蛋白激酶调节剂及其应用方法
|
|
EP2947086B1
(en)
|
2013-08-12 |
2018-01-03 |
Taiho Pharmaceutical Co., Ltd. |
Novel fused pyrimidine compound or salt thereof
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
LT3702373T
(lt)
|
2013-09-13 |
2022-11-10 |
Beigene Switzerland Gmbh |
Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
|
|
CN104262328B
(zh)
*
|
2013-09-18 |
2016-09-07 |
北京韩美药品有限公司 |
抑制btk和/或jak3激酶活性的化合物
|
|
KR20160063366A
(ko)
|
2013-10-21 |
2016-06-03 |
메르크 파텐트 게엠베하 |
Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도
|
|
CN111265531B
(zh)
|
2013-10-25 |
2023-11-10 |
药品循环有限责任公司 |
治疗和预防移植物抗宿主病的方法
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
NZ715903A
(en)
|
2014-01-30 |
2017-06-30 |
Signal Pharm Llc |
Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
|
|
US11039620B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US9622483B2
(en)
|
2014-02-19 |
2017-04-18 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
US11039621B2
(en)
|
2014-02-19 |
2021-06-22 |
Corning Incorporated |
Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
|
|
CN104860941B
(zh)
*
|
2014-02-25 |
2017-03-22 |
上海海雁医药科技有限公司 |
2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
|
|
EP4019518A1
(en)
|
2014-02-28 |
2022-06-29 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
US20170173011A1
(en)
*
|
2014-03-07 |
2017-06-22 |
Celgene Avilomics Research, Inc. |
Methods of treating a bruton's tyrosine kinase disease or disorder
|
|
CN106459063A
(zh)
|
2014-04-11 |
2017-02-22 |
北卡罗来纳-查佩尔山大学 |
Mertk‑特异性嘧啶化合物
|
|
JP6321821B2
(ja)
|
2014-04-14 |
2018-05-09 |
シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． |
２，３，４，６−４置換ベンゼン−１，５−ジアミン誘導体、その製造方法および医薬品における使用
|
|
JP2017514805A
(ja)
*
|
2014-04-16 |
2017-06-08 |
シグナル ファーマシューティカルズ，エルエルシー |
Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
|
|
WO2015158310A1
(zh)
*
|
2014-04-18 |
2015-10-22 |
山东轩竹医药科技有限公司 |
一种酪氨酸激酶抑制剂及其用途
|
|
CN104130265B
(zh)
*
|
2014-04-29 |
2017-01-25 |
苏州景泓生物技术有限公司 |
一种含有螺环或桥环的嘧啶类化合物
|
|
GB201410430D0
(en)
|
2014-06-11 |
2014-07-23 |
Redx Pharma Ltd |
Compounds
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
CN105315285B
(zh)
*
|
2014-07-25 |
2017-12-08 |
上海海雁医药科技有限公司 |
2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途
|
|
CR20170076A
(es)
|
2014-08-04 |
2017-06-26 |
Nuevolution As |
Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
|
|
CN117164657A
(zh)
|
2014-08-12 |
2023-12-05 |
莫纳什大学 |
定向淋巴的前药
|
|
US10005760B2
(en)
|
2014-08-13 |
2018-06-26 |
Celgene Car Llc |
Forms and compositions of an ERK inhibitor
|
|
ES2914099T3
(es)
*
|
2014-08-25 |
2022-06-07 |
Salk Inst For Biological Studi |
Inhibidores novedosos de ULK1 y métodos de uso de los mismos
|
|
CN105481778B
(zh)
*
|
2014-09-16 |
2019-06-04 |
深圳微芯生物科技股份有限公司 |
嘧啶衍生物、其制备方法及其应用
|
|
CN105399686B
(zh)
*
|
2014-09-16 |
2018-05-22 |
深圳微芯生物科技有限责任公司 |
嘧啶衍生物、其制备方法及其应用
|
|
CN105399685B
(zh)
*
|
2014-09-16 |
2018-05-22 |
深圳微芯生物科技有限责任公司 |
作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用
|
|
AU2015317741B2
(en)
|
2014-09-17 |
2020-01-16 |
Bristol-Myers Squibb Company |
MK2 inhibitors and uses thereof
|
|
PL3205650T3
(pl)
*
|
2014-10-11 |
2021-12-06 |
Shanghai Hansoh Biomedical Co., Ltd. |
Inhibitor EGFR i jego otrzymywanie i zastosowanie
|
|
EP3206691B1
(en)
|
2014-10-14 |
2018-09-19 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
KR102754019B1
(ko)
|
2014-10-29 |
2025-01-14 |
바이시클러드 리미티드 |
Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
|
|
CN105601573B
(zh)
|
2014-11-24 |
2021-07-02 |
中国科学院上海药物研究所 |
2-氨基嘧啶类化合物及其药物组合物和应用
|
|
JP2017537327A
(ja)
*
|
2014-12-11 |
2017-12-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ｂｔｋ阻害剤のアッセイ
|
|
EP3233808B1
(en)
|
2014-12-16 |
2021-07-14 |
Signal Pharmaceuticals, LLC |
Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin
|
|
WO2016100310A1
(en)
|
2014-12-16 |
2016-06-23 |
Signal Pharmaceuticals, Llc |
Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
|
|
CA2975260C
(en)
|
2015-01-29 |
2024-05-21 |
Signal Pharmaceuticals Llc |
Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
|
|
DK3120852T3
(da)
*
|
2015-01-30 |
2019-07-29 |
Taiho Pharmaceutical Co Ltd |
Præventivt og/eller terapeutisk middel til immunsygdomme
|
|
WO2016121954A1
(ja)
|
2015-01-30 |
2016-08-04 |
大鵬薬品工業株式会社 |
縮合ピリミジン化合物の新規な塩及びその結晶
|
|
SG11201706287PA
(en)
|
2015-02-20 |
2017-09-28 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
ES2930585T3
(es)
|
2015-02-27 |
2022-12-19 |
Nimbus Lakshmi Inc |
Inhibidores de TYK2 y usos de los mismos
|
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
KR20180041119A
(ko)
*
|
2015-07-09 |
2018-04-23 |
메르크 파텐트 게엠베하 |
Btk 억제제로서 피리미딘 유도체 및 이의 용도
|
|
ES2994877T3
(en)
|
2015-07-24 |
2025-02-03 |
Celgene Corp |
Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
|
|
MX2018002554A
(es)
|
2015-08-31 |
2018-08-14 |
Pharmacyclics Llc |
Combinaciones de inhibidores de btk para tratar mieloma multiple.
|
|
JP6802263B2
(ja)
|
2015-09-02 |
2020-12-16 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
EP3347340A4
(en)
|
2015-09-08 |
2019-01-23 |
Monash University |
LYMPHENLEITUNGSPRODRUGS
|
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
|
CN114685516A
(zh)
|
2015-09-16 |
2022-07-01 |
洛克索肿瘤学股份有限公司 |
用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
|
|
CN106554347B
(zh)
*
|
2015-09-25 |
2020-10-30 |
浙江博生医药有限公司 |
Egfr激酶抑制剂及其制备方法和应用
|
|
WO2017059702A1
(en)
|
2015-10-09 |
2017-04-13 |
Acea Biosciences, Inc |
Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
|
|
US10457669B2
(en)
*
|
2015-10-21 |
2019-10-29 |
Otsuka Pharmaceutical Co., Ltd. |
Benzolactam compounds as protein kinase inhibitors
|
|
AU2016342027B2
(en)
|
2015-10-23 |
2021-05-13 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
|
EP3389664A4
(en)
|
2015-12-14 |
2020-01-08 |
Raze Therapeutics Inc. |
MTHFD2 CAFFEINE INHIBITORS AND USE THEREOF
|
|
ES2828431T3
(es)
|
2015-12-16 |
2021-05-26 |
Loxo Oncology Inc |
Compuestos útiles como inhibidores de cinasa
|
|
CN107021963A
(zh)
|
2016-01-29 |
2017-08-08 |
北京诺诚健华医药科技有限公司 |
吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
|
|
EP3426244B1
(en)
|
2016-03-09 |
2023-06-07 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
|
PT3426243T
(pt)
|
2016-03-09 |
2021-08-19 |
Raze Therapeutics Inc |
Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos
|
|
US10709708B2
(en)
|
2016-03-17 |
2020-07-14 |
The University Of North Carolina At Chapel Hill |
Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
|
|
WO2017177230A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
|
CN105968056A
(zh)
*
|
2016-05-28 |
2016-09-28 |
大连医科大学 |
二芳基嘧啶类化合物，组合物及用途
|
|
CA3027500A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
WO2017223229A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
Ｃｘｃｒ４阻害剤およびその使用
|
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
|
EP4509183A3
(en)
|
2016-08-16 |
2025-05-21 |
BeiGene Switzerland GmbH |
Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
AU2017313085B2
(en)
|
2016-08-19 |
2024-06-20 |
Beone Medicines I Gmbh |
Use of a combination comprising a Btk inhibitor for treating cancers
|
|
CN106316886A
(zh)
*
|
2016-08-24 |
2017-01-11 |
泰州精英化成医药科技有限公司 |
顺式‑3‑（叔丁氧羰基氨基）环己烷甲酸的制备方法
|
|
MX390121B
(es)
|
2016-09-19 |
2025-03-20 |
Mei Pharma Inc |
Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
|
|
CN115448916B
(zh)
|
2016-10-14 |
2026-04-28 |
武田药品工业株式会社 |
Tyk2抑制剂及其用途
|
|
JP7082120B2
(ja)
|
2016-10-21 |
2022-06-07 |
ニンバス ラクシュミ， インコーポレイテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
CN107973754B
(zh)
*
|
2016-10-25 |
2020-04-14 |
清华大学 |
一种小分子抑制剂及其制备方法与其在多发性骨髓瘤治疗中的应用
|
|
JP2020023441A
(ja)
*
|
2016-11-02 |
2020-02-13 |
国立大学法人九州大学 |
Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物
|
|
MA46783A
(fr)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
Polythérapie de type thérapie cellulaire t et inhibiteur de btk
|
|
WO2018089499A1
(en)
|
2016-11-08 |
2018-05-17 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
|
US11730819B2
(en)
|
2016-12-23 |
2023-08-22 |
Bicycletx Limited |
Peptide derivatives having novel linkage structures
|
|
CN106632273A
(zh)
*
|
2016-12-29 |
2017-05-10 |
大连医科大学 |
含唑杂环的嘧啶类化合物，组合物及其用途
|
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
CN108329274B
(zh)
*
|
2017-01-13 |
2021-09-03 |
正大天晴药业集团股份有限公司 |
布鲁顿酪氨酸激酶抑制剂
|
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
CN108498477A
(zh)
*
|
2017-02-27 |
2018-09-07 |
江苏奥赛康药业股份有限公司 |
一种2-氨基嘧啶类化合物的药用组合物及其制备方法
|
|
TWI868528B
(zh)
|
2017-03-08 |
2025-01-01 |
日商武田藥品工業股份有限公司 |
Ｔｙｋ２抑制劑之生產方法
|
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
|
US11498922B2
(en)
|
2017-04-07 |
2022-11-15 |
ACEA Therapeutics, Inc. |
Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide
|
|
SI3609886T1
(sl)
|
2017-04-14 |
2024-05-31 |
Biogen Ma Inc. |
Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
ES2959860T3
(es)
|
2017-06-22 |
2024-02-28 |
Celgene Corp |
Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B
|
|
CN111032678A
(zh)
|
2017-06-26 |
2020-04-17 |
拜西克尔德有限公司 |
具有可检测部分的双环肽配体和其用途
|
|
KR102757960B1
(ko)
|
2017-06-26 |
2025-01-22 |
베이진 엘티디 |
간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
|
|
WO2019023468A1
(en)
|
2017-07-28 |
2019-01-31 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
ES2926195T3
(es)
|
2017-08-04 |
2022-10-24 |
Bicycletx Ltd |
Ligandos peptídicos bicíclicos específicos de CD137
|
|
US11377449B2
(en)
|
2017-08-12 |
2022-07-05 |
Beigene, Ltd. |
BTK inhibitors with improved dual selectivity
|
|
EP3668550A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
|
WO2019034866A1
(en)
|
2017-08-14 |
2019-02-21 |
Bicyclerd Limited |
BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
|
|
CN111032630B
(zh)
*
|
2017-08-18 |
2022-12-16 |
北京韩美药品有限公司 |
一种化合物，其药物组合物及其用途及应用
|
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
|
WO2019046491A1
(en)
|
2017-08-29 |
2019-03-07 |
Ariya Therapeutics, Inc. |
LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
|
|
KR102383561B1
(ko)
*
|
2017-09-07 |
2022-04-06 |
한국화학연구원 |
테트라히드로이소퀴놀린기로 치환된 피리미딘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 조성물
|
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス， インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
WO2019099311A1
(en)
|
2017-11-19 |
2019-05-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
|
WO2019126378A1
(en)
|
2017-12-19 |
2019-06-27 |
Ariya Therapeutics, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
|
JP7377207B2
(ja)
|
2018-01-29 |
2023-11-09 |
メルク パテント ゲーエムベーハー |
Ｇｃｎ２阻害剤およびその使用
|
|
EP4616913A3
(en)
|
2018-01-29 |
2025-12-10 |
Merck Patent GmbH |
Gcn2 inhibitors and uses thereof
|
|
TWI798334B
(zh)
|
2018-01-31 |
2023-04-11 |
大陸商迪哲（江蘇）醫藥股份有限公司 |
Ｅｒｂｂ／ｂｔｋ抑制劑
|
|
AU2019224659A1
(en)
|
2018-02-23 |
2020-10-15 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
EP3759086A1
(en)
|
2018-02-27 |
2021-01-06 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of tcr-nck interaction
|
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
|
WO2019209757A1
(en)
|
2018-04-24 |
2019-10-31 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
|
HUE067936T2
(hu)
|
2018-04-24 |
2024-11-28 |
Merck Patent Gmbh |
Proliferáció-gátló vegyületek és alkalmazásuk
|
|
MD3784664T2
(ro)
|
2018-04-26 |
2025-06-30 |
Pfizer |
Derivați de 2-amino-piridină sau de 2-amino-pirimidină utilizați ca inhibitori de kinaze dependente de cicline
|
|
JP7410877B2
(ja)
|
2018-05-03 |
2024-01-10 |
ジュノー セラピューティクス インコーポレイテッド |
キメラ抗原受容体（ｃａｒ）ｔ細胞療法とキナーゼ阻害剤の併用療法
|
|
MX2020011718A
(es)
|
2018-05-04 |
2021-02-15 |
Incyte Corp |
Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
|
|
ES3061844T3
(en)
|
2018-05-04 |
2026-04-07 |
Incyte Corp |
Salts of an fgfr inhibitor
|
|
IL314362A
(en)
|
2018-06-15 |
2024-09-01 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and their uses
|
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
EP3817822A4
(en)
|
2018-07-06 |
2022-07-27 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
US11066404B2
(en)
|
2018-10-11 |
2021-07-20 |
Incyte Corporation |
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
|
|
CA3115088A1
(en)
|
2018-10-15 |
2020-04-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
|
US10919937B2
(en)
|
2018-10-23 |
2021-02-16 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
|
CN109608444B
(zh)
*
|
2018-11-27 |
2022-02-11 |
中国药科大学 |
含异吲哚啉酮的erk抑制剂及其制备方法与用途
|
|
CN113271938A
(zh)
|
2018-11-30 |
2021-08-17 |
林伯士拉克许米公司 |
Tyk2抑制剂和其用途
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
CN113474045A
(zh)
|
2018-12-21 |
2021-10-01 |
拜斯科技术开发有限公司 |
Pd-l1特异性的双环肽配体
|
|
US12551567B2
(en)
|
2018-12-21 |
2026-02-17 |
Bicyclerd Limited |
Bicyclic peptide ligands specific for PD-L1
|
|
AU2020212001A1
(en)
|
2019-01-23 |
2021-07-22 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
|
CN109776495A
(zh)
*
|
2019-01-31 |
2019-05-21 |
李佳睿 |
抗肿瘤化合物及其制备方法与用途
|
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
|
US11384083B2
(en)
|
2019-02-15 |
2022-07-12 |
Incyte Corporation |
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
|
|
TW202100520A
(zh)
|
2019-03-05 |
2021-01-01 |
美商英塞特公司 |
作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
EA202192552A1
(ru)
|
2019-03-29 |
2021-12-17 |
Астразенека Аб |
Осимертиниб для применения в лечении немелкоклеточного рака легкого
|
|
WO2020205560A1
(en)
|
2019-03-29 |
2020-10-08 |
Incyte Corporation |
Sulfonylamide compounds as cdk2 inhibitors
|
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
|
US11440914B2
(en)
|
2019-05-01 |
2022-09-13 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
US11447494B2
(en)
|
2019-05-01 |
2022-09-20 |
Incyte Corporation |
Tricyclic amine compounds as CDK2 inhibitors
|
|
EP3966206B1
(en)
|
2019-05-10 |
2023-08-09 |
Deciphera Pharmaceuticals, LLC |
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
EP3966207B1
(en)
|
2019-05-10 |
2023-11-01 |
Deciphera Pharmaceuticals, LLC |
Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
WO2020243423A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2020249001A1
(zh)
|
2019-06-10 |
2020-12-17 |
百济神州瑞士有限责任公司 |
一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
|
|
WO2020251971A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020251972A1
(en)
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
JP7626722B2
(ja)
|
2019-06-17 |
2025-02-04 |
デシフェラ・ファーマシューティカルズ，エルエルシー |
アミノピリミジンアミドオートファジー阻害剤およびその使用方法
|
|
US12473264B2
(en)
|
2019-06-18 |
2025-11-18 |
Purdue Research Foundation |
Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
TWI860386B
(zh)
|
2019-07-30 |
2024-11-01 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
|
CN110305140B
(zh)
*
|
2019-07-30 |
2020-08-04 |
上海勋和医药科技有限公司 |
二氢吡咯并嘧啶类选择性jak2抑制剂
|
|
CN116348458A
(zh)
|
2019-08-14 |
2023-06-27 |
因赛特公司 |
作为cdk2抑制剂的咪唑基嘧啶基胺化合物
|
|
CN115038688A
(zh)
|
2019-09-11 |
2022-09-09 |
文森雷生物科学股份有限公司 |
Usp30抑制剂及其用途
|
|
PH12022550605A1
(en)
|
2019-09-13 |
2023-09-25 |
Nimbus Saturn Inc |
Hpk1 antagonists and uses thereof
|
|
CN112574207B
(zh)
*
|
2019-09-30 |
2023-04-11 |
南京药石科技股份有限公司 |
Erk1/2蛋白激酶抑制剂及其用途
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN119930611A
(zh)
|
2019-10-11 |
2025-05-06 |
因赛特公司 |
作为cdk2抑制剂的双环胺
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US20220387430A1
(en)
*
|
2019-11-08 |
2022-12-08 |
Shenzhen Chipscreen Biosciences, Co., Ltd. |
Use of compound in preventing or treating graft versus host disease
|
|
JP2023503385A
(ja)
*
|
2019-11-26 |
2023-01-27 |
シェンチェン チップスクリーン バイオサイエンシズ カンパニー、リミテッド |
非晶質形態の芳香族複素環式化合物を含む組成物、並びにその調製方法及びその使用
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
BR112022010754A2
(pt)
|
2019-12-05 |
2022-08-23 |
Anakuria Therapeutics Inc |
Análogos de rapamicina e usos dos mesmos
|
|
EP4072591A4
(en)
|
2019-12-10 |
2024-06-05 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADER AND USES THEREOF
|
|
JP2023509366A
(ja)
|
2019-12-17 |
2023-03-08 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
WO2021127283A2
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2020408107B2
(en)
|
2019-12-20 |
2026-04-23 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
AU2020405446A1
(en)
|
2019-12-20 |
2022-05-26 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
CN115297931A
(zh)
|
2019-12-23 |
2022-11-04 |
凯麦拉医疗公司 |
Smarca降解剂和其用途
|
|
US12569485B2
(en)
|
2019-12-23 |
2026-03-10 |
Kymera Therapeutics, Inc. |
SMARCA inhibitors and uses thereof
|
|
WO2021138391A1
(en)
|
2019-12-30 |
2021-07-08 |
Tyra Biosciences, Inc. |
Indazole compounds
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN111620852B
(zh)
*
|
2020-01-19 |
2023-05-09 |
镇江植生源农业科技有限公司 |
一种5-氯-嘧啶-2,4-二胺类化合物及其制备方法和应用
|
|
AU2021217172A1
(en)
|
2020-02-05 |
2022-09-22 |
Monash University |
Lipid prodrugs of neurosteroids
|
|
CN115515588A
(zh)
|
2020-02-14 |
2022-12-23 |
萨克生物研究学院 |
大环ulk1/2抑制剂
|
|
MX2022010944A
(es)
|
2020-03-03 |
2022-11-09 |
Pic Therapeutics Inc |
Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
|
|
IL296451B2
(en)
|
2020-03-19 |
2026-05-01 |
Kymera Therapeutics Inc |
MDM2 joints and their uses
|
|
US11613532B2
(en)
|
2020-03-31 |
2023-03-28 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
EP4126874A1
(en)
|
2020-03-31 |
2023-02-08 |
Nuevolution A/S |
Compounds active towards nuclear receptors
|
|
AR121759A1
(es)
|
2020-04-07 |
2022-07-06 |
Mitobridge Inc |
Inhibidores de cd38
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
|
CN111646978B
(zh)
*
|
2020-06-11 |
2021-12-21 |
浙江大学 |
N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用
|
|
WO2022006518A1
(en)
*
|
2020-07-02 |
2022-01-06 |
The Cleveland Clinic Foundation |
Compounds and methods of promoting oligodendrocyte precursor differentiation
|
|
WO2022011091A1
(en)
|
2020-07-09 |
2022-01-13 |
Usher Iii Initiative, Inc. |
Treatment of cancer, inflammatory diseases and autoimmune diseases
|
|
CA3189761A1
(en)
|
2020-08-03 |
2022-02-10 |
Gemma Mudd |
Peptide-based linkers
|
|
KR20230074721A
(ko)
|
2020-08-17 |
2023-05-31 |
바이사이클티엑스 리미티드 |
Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
|
|
KR20230107207A
(ko)
*
|
2020-09-22 |
2023-07-14 |
베이진 엘티디 |
Egfr 억제제로서의 인돌린 화합물 및 유도체
|
|
WO2022072632A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Scorpion Therapeutics, Inc. |
Bicyclic compounds for use in the treatment cancer
|
|
JP2023546996A
(ja)
|
2020-10-23 |
2023-11-08 |
ニンバス クロソー， インコーポレイテッド |
Ｃｔｐｓ１阻害剤およびその使用
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
IL303376A
(en)
|
2020-12-02 |
2023-08-01 |
Ikena Oncology Inc |
Tead inhibitors and uses thereof
|
|
EP4259144A4
(en)
|
2020-12-09 |
2025-08-20 |
Kymera Therapeutics Inc |
SMARCA DEGRADING AGENTS AND THEIR USES
|
|
WO2022147465A1
(en)
|
2020-12-30 |
2022-07-07 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Ｇｐｒ８４アンタゴニストおよびその使用
|
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
TW202245788A
(zh)
|
2021-02-15 |
2022-12-01 |
美商凱麥拉醫療公司 |
Irak4降解劑及其用途
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
CN115160319B
(zh)
*
|
2021-04-01 |
2023-12-26 |
西安新通药物研究股份有限公司 |
含1,3-苯并二氧戊环结构的化合物及其制备方法与用途
|
|
WO2022212893A1
(en)
|
2021-04-02 |
2022-10-06 |
Biogen Ma Inc. |
Combination treatment methods of multiple sclerosis
|
|
EP4319756A4
(en)
|
2021-04-09 |
2025-02-26 |
Nimbus Clio, Inc. |
CBL-B MODULATORS AND USES THEREOF
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11981671B2
(en)
|
2021-06-21 |
2024-05-14 |
Incyte Corporation |
Bicyclic pyrazolyl amines as CDK2 inhibitors
|
|
TW202315621A
(zh)
|
2021-08-25 |
2023-04-16 |
美商皮克醫療公司 |
Ｅｉｆ４ｅ抑制劑及其用途
|
|
JP2024532276A
(ja)
|
2021-08-25 |
2024-09-05 |
ピク セラピューティクス， インコーポレイテッド |
ｅＩＦ４Ｅ阻害剤及びその使用
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
US11976073B2
(en)
|
2021-12-10 |
2024-05-07 |
Incyte Corporation |
Bicyclic amines as CDK2 inhibitors
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
IL314437A
(en)
|
2022-01-31 |
2024-09-01 |
Kymera Therapeutics Inc |
IRAK joints and their uses
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
US12233056B2
(en)
|
2022-04-06 |
2025-02-25 |
Syntara Limited |
Lysyl oxidase inhibitors for treating myeloid malignancies
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
KR20250040894A
(ko)
|
2022-05-25 |
2025-03-25 |
이케나 온콜로지, 인코포레이티드 |
Mek 억제제 및 이의 용도
|
|
US11786531B1
(en)
|
2022-06-08 |
2023-10-17 |
Beigene Switzerland Gmbh |
Methods of treating B-cell proliferative disorder
|
|
JP2025527247A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
|
|
JP2025527248A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
|
|
JP2025527250A
(ja)
|
2022-08-02 |
2025-08-20 |
リミナル・バイオサイエンシーズ・リミテッド |
ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
|
|
CN115448906B
(zh)
*
|
2022-09-26 |
2024-04-02 |
深圳大学 |
一种2-苯胺基嘧啶类衍生物及其制备方法与应用
|
|
TW202430148A
(zh)
|
2022-11-22 |
2024-08-01 |
美商皮克醫療公司 |
ｅＩＦ４Ｅ抑制劑及其用途
|
|
EP4615455A2
(en)
|
2023-06-23 |
2025-09-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
AU2024344754A1
(en)
|
2023-09-21 |
2026-04-02 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
|
|
TW202515850A
(zh)
*
|
2023-09-22 |
2025-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
雜芳基類化合物、其製備方法及其在醫藥上的應用
|
|
CN119707835A
(zh)
*
|
2024-11-25 |
2025-03-28 |
沈阳药科大学 |
2-氨基嘧啶-5-甲酰胺类化合物及用于制备治疗和/或预防癌症药物中的用途
|